Study of deferoxamine in subcutaneous profusion treatment of iron overload in myelodysplastic syndromes;Estudio del tratamiento con desferroxamina en perfusión subcutánea para la sobrecarga de hierro en pacientes con síndrome mielodisplásico

Medicina Clinica

Volumn 124, Issue 17, 2005, Pages 645-647

  González, Fernando Ataúlfo ^a   Arrizabalaga, Beatriz ^b   Villegas, Ana ^b   Alonso, Dora ^b   Castro, Mercedes ^b   Remacha, Ángel ^b   Del Arco, Aurora ^b   Nuñez, Guillermo Martín ^b   Duran J ^b   Fernandez Fuertes I ^b   Gilsanz, F ^b   De Las Heras, G ^b   Hernandez J A ^b   Marchante, A ^b   Murga, M J ^b   Penalver M ^b   Sanchez Jacob M ^b   Somolinos, N ^b  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b NONE

Author keywords

Desferrioxamine; Iron overload; Myelodysplastic syndrome

Indexed keywords

DEFEROXAMINE; FERRITIN; HEMOGLOBIN;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; IRON OVERLOAD; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; OPEN STUDY; REFRACTORY ANEMIA; SIDEROBLASTIC ANEMIA;

EID: 20844447672     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13074739     Document Type: Article

References (12)

1. Aul C, Gattermann N, Schneider W. Age related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol. 1992; 82:358-67.
2. Scafer A, Cheron RG, Dluhy R, Cooper B, Gleason RE, Soeldner JS, et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med. 1981;304:319-24.
3. Propper RD, Cooper B, Rufo RR, Nienhuis AW, Anderson WF, Bunn HF, et al. Continuous subcutaneous administration of deferoxamine in patients with iron overload. N Engl J Med. 1977; 297:418-23.
4. Hoffbrand AV, Wonke B. Result of long-term subcutaneous desferroxamine therapy. Ball Clin Haematol. 1989;2:345-62.
5. Villegas A. Quelantes del hierro. Med Clin (Barc). 1994;102:739-41.
6. Hemsen Jensen PD, Heickendorff L, Pedersen B. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol. 1996;94:288-99.
7. Rodriguez Galindo C, Ortega Aramburu JJ, Alonso JL, Albisu M, Casadaliga J, Diaz de Heredia C, et al. Evaluación de la eficacia del tratamiento con eferoxamina en pacientes con talasemia mayor. Med Clin (Barc). 1994;102:721-4.
8. Jensen PD, Jensen FT, Christiansen T, Ellegaard J. Evaluation of transfusional iron overload before and during iron chelation by magnetic resonance imaging of the liver and determination of serum ferritin in adult non-thalassemic patients. Br J Haematol. 1995;89:880-9.
9. Alessandrino EP, Amadori S, Barosi G, Cazzola M, Grossa A, Liberato LN, et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica. 2002;87:1286-306.
10. Franchini M, Gandini G, de Gironcoli M, Vassanelli A, Borgna-Pignatti C, Aprili G. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. Blood. 2000;95:2776-9.
11. Borgna-Pignatti C, Franchini M, Gandini G, Vassanelli A, De Gironcoli M, Aprili G. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload. Haematologica. 1998;83:788-90.
12. Hoffbrand AV. Oral iron chelation therapy. Semin Hematol. 1996;33:1-8.